Literature DB >> 16942863

Substance misuse and cognitive functioning in early psychosis: a 2 year follow-up.

Amanda McCleery1, Jean Addington, Donald Addington.   

Abstract

High comorbidity exists between substance use and psychosis. Since substance use has been shown to negatively impact cognitive functioning in the general population, there is concern about the impact of substance use on already compromised cognitive functioning. However, the literature regarding the effects of substance use on cognition in early psychosis patients is inconclusive. The purpose of this study was to examine the relationship between substance misuse and cognitive functioning in a first episode psychosis sample for 2 years following admission to a specialized early psychosis program. One hundred and eighty-three subjects were assessed at baseline, 147 at 1 year and 116 at 2 years using the Case Manager Rating Scale (CMRS) for substance use and a comprehensive cognitive battery. Approximately 50% of subjects engaged in substance misuse at baseline, which did decrease over follow-up. At baseline, the cognitive performance of patients with both mild use and misuse was significantly better than non-users. These same patients demonstrated better performance at follow-up. These results do not provide evidence for a negative impact of substance use on cognition.

Entities:  

Mesh:

Year:  2006        PMID: 16942863     DOI: 10.1016/j.schres.2006.06.040

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  12 in total

1.  Neurocognitive functioning of individuals with schizophrenia: using and not using drugs.

Authors:  Amber L Bahorik; Christina E Newhill; Shaun M Eack
Journal:  Schizophr Bull       Date:  2013-07-24       Impact factor: 9.306

2.  Attention/vigilance in schizophrenia: performance results from a large multi-site study of the Consortium on the Genetics of Schizophrenia (COGS).

Authors:  Keith H Nuechterlein; Michael F Green; Monica E Calkins; Tiffany A Greenwood; Raquel E Gur; Ruben C Gur; Laura C Lazzeroni; Gregory A Light; Allen D Radant; Larry J Seidman; Larry J Siever; Jeremy M Silverman; Joyce Sprock; William S Stone; Catherine A Sugar; Neal R Swerdlow; Debby W Tsuang; Ming T Tsuang; Bruce I Turetsky; David L Braff
Journal:  Schizophr Res       Date:  2015-03-04       Impact factor: 4.939

3.  A prospective 2-year study of emergency department patients with early-phase primary psychosis or substance-induced psychosis.

Authors:  Robert E Drake; Carol L M Caton; Haiyi Xie; Eustace Hsu; Prakash Gorroochurn; Sharon Samet; Deborah S Hasin
Journal:  Am J Psychiatry       Date:  2011-03-31       Impact factor: 18.112

Review 4.  The Role of Endocannabinoid Signaling in Cortical Inhibitory Neuron Dysfunction in Schizophrenia.

Authors:  David W Volk; David A Lewis
Journal:  Biol Psychiatry       Date:  2015-06-19       Impact factor: 13.382

5.  Inferior performance on selected neuropsychological tests in abstinent schizophrenia patients who have used cannabis.

Authors:  Krzysztof Krysta; Irena Krupka-Matuszczyk; Małgorzata Janas-Kozik; Małgorzata Stachowicz; Jan Szymszal; Janusz K Rybakowski
Journal:  Med Sci Monit       Date:  2012-09

6.  The Cannabis Pathway to Non-Affective Psychosis may Reflect Less Neurobiological Vulnerability.

Authors:  Else-Marie Løberg; Siri Helle; Merethe Nygård; Jan Øystein Berle; Rune A Kroken; Erik Johnsen
Journal:  Front Psychiatry       Date:  2014-11-18       Impact factor: 4.157

7.  Cannabis use and cognition in schizophrenia.

Authors:  Else-Marie Løberg; Kenneth Hugdahl
Journal:  Front Hum Neurosci       Date:  2009-11-24       Impact factor: 3.169

8.  Susceptibility of the adolescent brain to cannabinoids: long-term hippocampal effects and relevance to schizophrenia.

Authors:  K A Gleason; S G Birnbaum; A Shukla; S Ghose
Journal:  Transl Psychiatry       Date:  2012-11-27       Impact factor: 6.222

9.  Naturalistic follow-up of co-morbid substance use in schizophrenia: the West London first-episode study.

Authors:  I Harrison; E M Joyce; S H Mutsatsa; S B Hutton; V Huddy; M Kapasi; T R E Barnes
Journal:  Psychol Med       Date:  2007-05-29       Impact factor: 7.723

10.  Impact of substance use disorder on presentation and short-term course of schizophrenia.

Authors:  Rudraprosad Chakraborty; Arunima Chatterjee; Suprakash Chaudhury
Journal:  Psychiatry J       Date:  2014-04-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.